{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:07:51Z","timestamp":1795100871876,"version":"4.10.3"},"reference-count":178,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jbspin.2024.105790","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:43:14Z","timestamp":1728502994000},"page":"105790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"91","author":[{"given":"Bruno","family":"Fautrel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antoine","family":"Juge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Rempenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Brocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Carvajal","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Gaujoux-Viala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Go\u00ebb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Senbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Escaffre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Daien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105790_bib0895","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib0900","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","article-title":"Update of French Society for Rheumatology recommendations for managing rheumatoid arthritis","volume":"86","author":"Daien","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib0905","first-page":"1018","article-title":"[Effectiveness of clinical guideline implementation strategies: systematic review of systematic reviews]","volume":"24","author":"Durieux","year":"2000","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jbspin.2024.105790_bib0910","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014\u00a0update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0920","doi-asserted-by":"crossref","first-page":"105592","DOI":"10.1016\/j.jbspin.2023.105592","article-title":"Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases","volume":"90","author":"Avouac","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib0925","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016\u00a0update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0930","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016\u00a0update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0935","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022\u00a0update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0940","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022\u00a0update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0945","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019\u00a0update of the EULAR recommendations for management of rheumatoid arthritis","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0950","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022\u00a0update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0955","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","article-title":"EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis","volume":"71","author":"Gerlag","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0960","doi-asserted-by":"crossref","first-page":"e001768","DOI":"10.1136\/rmdopen-2021-001768","article-title":"A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"7","author":"Mankia","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib0965","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2021-220884","article-title":"EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"80","author":"Mankia","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0970","series-title":"M\u00e9thodes d\u2019\u00e9laboration des recommandations de bonne pratique","year":"2014"},{"key":"10.1016\/j.jbspin.2024.105790_bib0975","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022\u00a0update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib0980","year":"2019","journal-title":"RoB 2: a revised Cochrane risk-of-bias tool for randomized trials"},{"key":"10.1016\/j.jbspin.2024.105790_bib0985","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib0990","doi-asserted-by":"crossref","first-page":"e003059","DOI":"10.1136\/rmdopen-2023-003059","article-title":"Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review","volume":"9","author":"Matteson","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib0995","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"63","author":"Brouwers","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1000","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jbspin.2014.12.014","article-title":"Include patient education in daily practice: promoting the patient-centered care approach","volume":"82","author":"Beauvais","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1005","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1010","series-title":"\u00c9ducation th\u00e9rapeutique du patient (ETP)","year":"2014"},{"key":"10.1016\/j.jbspin.2024.105790_bib1015","doi-asserted-by":"crossref","first-page":"e000404","DOI":"10.1136\/rmdopen-2016-000404","article-title":"Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016\u00a0update of EULAR recommendations for the management of early arthritis","volume":"3","author":"Daien","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1020","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/rmdopen-2016-000406","article-title":"Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016\u00a0update of the EULAR recommendations for the management of early arthritis","volume":"3","author":"Hua","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/ard.61.4.290","article-title":"Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide","volume":"61","author":"Emery","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.berh.2011.10.001","article-title":"Rheumatoid arthritis: economic consequences and potential benefits","volume":"25","author":"Fautrel","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/ard.2011.154583","article-title":"The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review","volume":"71","author":"ter Wee","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1040","doi-asserted-by":"crossref","first-page":"iv21","DOI":"10.1093\/rheumatology\/kes088","article-title":"Economic benefits of optimizing anchor therapy for rheumatoid arthritis","volume":"51","author":"Fautrel","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jval.2017.01.005","article-title":"Cost-effectiveness of TNF-blocker injection spacing for patients with established rheumatoid arthritis in remission: an economic evaluation from the spacing of TNF-blocker injections in rheumatoid arthritis trial","volume":"20","author":"Vanier","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jbspin.2024.105790_bib1055","doi-asserted-by":"crossref","first-page":"e001637","DOI":"10.1136\/rmdopen-2021-001637","article-title":"Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects","volume":"7","author":"Smolen","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jbspin.2018.03.002","article-title":"Biosimilars: an opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)","volume":"85","author":"Schaeverbeke","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1065","series-title":"Vers la sobri\u00e9t\u00e9 heureuse","author":"Rabhi","year":"2010"},{"key":"10.1016\/j.jbspin.2024.105790_bib1070","series-title":"La part du colibri\u00a0: l\u2019esp\u00e8ce humaine face \u00e0 son devenir","author":"Rabhi","year":"2014"},{"key":"10.1016\/j.jbspin.2024.105790_bib1075","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1093\/rheumatology\/keaa774","article-title":"Subclinical synovitis in arthralgia: how often does it result in clinical arthritis? Reflecting on starting points for disease-modifying anti-rheumatic drug treatment","volume":"60","author":"Rogier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-021-08846-5","article-title":"Systematic review and meta-analysis on the association of occupational exposure to free crystalline silica and rheumatoid arthritis","volume":"62","author":"Morotti","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard-2022-223134","article-title":"Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking","volume":"82","author":"Tang","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1090","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.3390\/jcm9103109","article-title":"Environment and lifestyle: their influence on the risk of RA","volume":"9","author":"Salliot","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5114\/reum.2020.98436","article-title":"The relationship between periodontal status and rheumatoid arthritis\u2013systematic review","volume":"58","author":"Samborska-Mazur","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1100","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2016-210431","article-title":"Long-term dietary quality and risk of developing rheumatoid arthritis in women","volume":"76","author":"Hu","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1105","doi-asserted-by":"crossref","first-page":"e35296","DOI":"10.1371\/journal.pone.0035296","article-title":"Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis","volume":"7","author":"Sokolove","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2024.105790_bib1110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2020-217066","article-title":"Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting","volume":"80","author":"Bemis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1115","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/rheumatology\/kex340","article-title":"The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia","volume":"56","author":"Ten Brinck","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1120","doi-asserted-by":"crossref","first-page":"105187","DOI":"10.1016\/j.jbspin.2021.105187","article-title":"Recommendations for the pragmatic use of ultrasound in rheumatoid arthritis by the GEISPER French group","volume":"88","author":"Mouterde","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1125","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/rheumatology\/kez436","article-title":"Improving the feasibility of MRI in clinically suspect arthralgia for prediction of rheumatoid arthritis by omitting scanning of the feet","volume":"59","author":"Boer","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13075-019-2002-z","article-title":"A search to the target tissue in which RA-specific inflammation starts: a detailed MRI study to improve identification of RA-specific features in the phase of clinically suspect arthralgia","volume":"21","author":"Matthijssen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2024.105790_bib1135","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/rheumatology\/keab830","article-title":"During development of rheumatoid arthritis, intermetatarsal bursitis may occur before clinical joint swelling: a large imaging study in patients with clinically suspect arthralgia","volume":"61","author":"Van Dijk","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1140","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.pec.2018.12.011","article-title":"Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: a randomized controlled trial","volume":"102","author":"Marshall","year":"2019","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.jbspin.2024.105790_bib1145","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/acr.23474","article-title":"Treating Early undifferentiated arthritis: a systematic review and meta-analysis of direct and indirect trial evidence","volume":"70","author":"Lopez-Olivo","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2024.105790_bib1150","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","article-title":"Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)","volume":"73","author":"Van Aken","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-018-1667-z","article-title":"Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial","volume":"20","author":"Stamm","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2024.105790_bib1160","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"Van Eijk","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1170","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/annrheumdis-2016-209272","article-title":"Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial","volume":"75","author":"Kuijper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1180","first-page":"3180","article-title":"Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial","volume":"74","author":"Deane","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105790_bib1190","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105790_bib1195","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105790_bib1200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1205","doi-asserted-by":"crossref","first-page":"e001591","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"Van Boheemen","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1210","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/rheumatology\/keac693","article-title":"A multidisciplinary lifestyle program for rheumatoid arthritis: the \u201cPlants for Joints\u201d randomized controlled trial","volume":"62","author":"Walrabenstein","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1215","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/acr.23837","article-title":"Impact and timing of smoking cessation on reducing risk of rheumatoid arthritis among women in the nurses\u2019 health studies","volume":"71","author":"Liu","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2024.105790_bib1220","doi-asserted-by":"crossref","first-page":"503.e1","DOI":"10.1016\/j.amjmed.2005.09.053","article-title":"Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women","volume":"119","author":"Costenbader","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022\u00a0revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1230","doi-asserted-by":"crossref","first-page":"105174","DOI":"10.1016\/j.jbspin.2021.105174","article-title":"Practical management of patients on anti-TNF therapy: practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)","volume":"88","author":"Sellam","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1235","doi-asserted-by":"crossref","first-page":"105221","DOI":"10.1016\/j.jbspin.2021.105221","article-title":"Practical Management of patients on anti-IL6R therapy: practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)","volume":"88","author":"Morel","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1240","doi-asserted-by":"crossref","first-page":"eS2","DOI":"10.1016\/S1297-319X(19)30154-X","article-title":"Practical management of patients on Janus kinase inhibitor (JAKi) therapy: practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR)","volume":"86","author":"Richez","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1245","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1250","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28\u00a0predicts the likelihood of achieving low disease activity at 1\u00a0year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1\u00a0trial","volume":"39","author":"Van Der Heijde","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-016-1028-8","article-title":"Optimal responses in disease activity scores to treatment in rheumatoid arthritis: is a DAS28\u00a0reduction of>1.2\u00a0sufficient?","volume":"18","author":"Mian","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2024.105790_bib1260","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/annrheumdis-2015-208324","article-title":"Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point","volume":"75","author":"Aletaha","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1265","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.090776","article-title":"Clinical activity after 12\u00a0weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2\u00a0years later","volume":"37","author":"Ichikawa","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1270","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1275","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3\u00a0trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1285","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/mr\/roab021","article-title":"Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3\u00a0study (FINCH 3)","volume":"32","author":"Atsumi","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1290","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1295","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1093\/rheumatology\/keab861","article-title":"Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3\u00a0program","volume":"61","author":"Peterfy","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1300","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs. its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1305","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/ard.2010.137695","article-title":"Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort","volume":"70","author":"Soubrier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1310","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M15-0919","article-title":"Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10\u00a0years of tight controlled treatment: a randomized trial","volume":"164","author":"Markusse","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1315","doi-asserted-by":"crossref","first-page":"105060","DOI":"10.1016\/j.jbspin.2020.07.009","article-title":"Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR","volume":"88","author":"Kedra","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1320","doi-asserted-by":"crossref","first-page":"e000245","DOI":"10.1136\/rmdopen-2016-000245","article-title":"Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data","volume":"2","author":"Granger","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1325","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/annrheumdis-2017-211268","article-title":"Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort","volume":"76","author":"Gaujoux-Viala","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1330","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1335","first-page":"3123","article-title":"Comparison of two dosing schedules for oral methotrexate (split-dose versus single-dose) once weekly in patients with active rheumatoid arthritis: a multicenter, open label, parallel group, randomized controlled trial (SMART study)","volume":"75","author":"Bhushan Prasad","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1340","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00296-016-3621-1","article-title":"Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis","volume":"37","author":"Schiff","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2024.105790_bib1345","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1355","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"Verschueren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1360","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","article-title":"Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial","volume":"74","author":"ter Wee","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1365","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","article-title":"Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial","volume":"73","author":"De Jong","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1370","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-202433","article-title":"Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1\u00a0study","volume":"73","author":"Takeuchi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1380","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105790_bib1385","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jconrel.2021.12.007","article-title":"Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: a randomized controlled clinical trial","volume":"341","author":"Metselaar","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.jbspin.2024.105790_bib1390","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/rheumatology\/keac582","article-title":"Favourable effect of a \u2018second hit\u2019 after 13\u00a0weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial","volume":"62","author":"Hartman","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1395","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/art.42245","article-title":"The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"74","author":"Krause","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1400","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1405","first-page":"3940","article-title":"Tapering of long-term low dose glucocorticoids in senior rheumatoid arthritis patients: follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial","volume":"74","author":"Almayali","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1410","doi-asserted-by":"crossref","first-page":"152109","DOI":"10.1016\/j.semarthrit.2022.152109","article-title":"Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA trial","volume":"57","author":"Hartman","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105790_bib1415","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021\u00a0American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1420","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/annrheumdis-2022-eular.1268","article-title":"POS0643\u00a0sustainability of response between upadacitinib and adalimumab in patients with rheumatoid arthritis: results through 3\u00a0years from the select-compare trial","volume":"81","author":"Nash","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1425","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/keac477","article-title":"Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE","volume":"62","author":"Mysler","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105790_bib1430","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1435","series-title":"EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots","year":"2019"},{"key":"10.1016\/j.jbspin.2024.105790_bib1440","series-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","year":"2021"},{"key":"10.1016\/j.jbspin.2024.105790_bib1445","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00228-022-03402-2","article-title":"JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study","volume":"78","author":"Gouverneur","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1450","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1455","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1460","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1465","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1470","unstructured":"Schaefer M, Meissner Y, Manger B, Berger S, Rockwitz K, Regierer A, et al. Incident malignancies in patients with rheumatoid arthritis in daily rheumatological care. Arthritis Rheumatol n.d.;75:3238\u201340."},{"key":"10.1016\/j.jbspin.2024.105790_bib1475","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1480","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48\u00a0weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1485","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1490","series-title":"Sci Abstr","article-title":"OP0045\u00a0EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritides and a history of cancer","author":"Sebbag","year":"2023"},{"key":"10.1016\/j.jbspin.2024.105790_bib1495","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1500","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","article-title":"Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study","volume":"76","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1505","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/ard.2007.085696","article-title":"The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study","volume":"68","author":"Finckh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1510","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-009-1349-y","article-title":"Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha","volume":"29","author":"De Stefano","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1515","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial","volume":"43","author":"Kaeley","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","article-title":"Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients","volume":"71","author":"Du Pan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1525","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105790_bib1530","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3899\/jrheum.151212","article-title":"Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review","volume":"43","author":"Curtis","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1540","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1545","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/rheumatology\/keq060","article-title":"Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA","volume":"49","author":"den Broeder","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1550","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1555","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jbspin.2018.02.002","article-title":"Therapeutic strategy for rheumatoid arthritis patients who have achieved remission","volume":"85","author":"Fautrel","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1565","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2024.105790_bib1570","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1575","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1580","doi-asserted-by":"crossref","first-page":"105319","DOI":"10.1016\/j.jbspin.2021.105319","article-title":"Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases","volume":"89","author":"Daien","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105790_bib1585","doi-asserted-by":"crossref","first-page":"210011","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jbspin.2024.105790_bib1590","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1595","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1513\/AnnalsATS.202107-876CME","article-title":"Airway disease in rheumatoid arthritis","volume":"19","author":"Matson","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jbspin.2024.105790_bib1600","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1605","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1610","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3899\/jrheum.200863","article-title":"Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease","volume":"48","author":"Kronzer","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1615","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.reuma.2019.05.007","article-title":"Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis","volume":"17","author":"Paulin","year":"2021","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jbspin.2024.105790_bib1620","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1625","series-title":"Screening programmes: a short guide","year":"2020"},{"key":"10.1016\/j.jbspin.2024.105790_bib1630","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.reuma.2019.06.001","article-title":"Analysis of clinical-analytical characteristics in patients with rheumatoid arthritis and interstitial lung disease: case-control study","volume":"17","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jbspin.2024.105790_bib1635","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1640","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10067-018-4382-x","article-title":"Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population","volume":"38","author":"Fu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12890-019-0875-x","article-title":"Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device)","volume":"19","author":"Manfredi","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1650","doi-asserted-by":"crossref","first-page":"406927","DOI":"10.1155\/2013\/406927","article-title":"Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease","volume":"2013","author":"Chen","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1655","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13075-019-1888-9","article-title":"A simplified lung ultrasound for the diagnosis of interstitial lung disease in connective tissue disease: a meta-analysis","volume":"21","author":"Xie","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2024.105790_bib1660","doi-asserted-by":"crossref","first-page":"1800869","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2024.105790_bib1665","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.semarthrit.2021.07.002","article-title":"MUC5B promoter variant rs35705950\u00a0and rheumatoid arthritis associated interstitial lung disease survival and progression","volume":"51","author":"Juge","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105790_bib1670","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1675","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1680","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2\u00a0study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1685","doi-asserted-by":"crossref","first-page":"152312","DOI":"10.1016\/j.semarthrit.2023.152312","article-title":"Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease","volume":"64","author":"Juge","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105790_bib1690","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2024.105790_bib1695","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1093\/rheumatology\/keac208","article-title":"The impact of disease severity measures on survival in U.S.\u00a0veterans with rheumatoid arthritis-associated interstitial lung disease","volume":"61","author":"Brooks","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1700","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2024.105790_bib1705","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1710","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","article-title":"Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study","volume":"60","author":"Ibfelt","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1715","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/art.38733","article-title":"Methotrexate and lung disease in rheumatoid arthritis: comment on the article by Conway et al","volume":"66","author":"Rojas-Serrano","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1720","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease\u00a0\u2013\u00a0improving outcomes over 25\u00a0years: a large multicentre UK study","volume":"60","author":"Kelly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1725","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122\u00a0cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105790_bib1730","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1735","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263\u00a0patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1740","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jbspin.2024.105790_bib1745","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2024.105790_bib1750","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10\u00a0years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105790_bib1755","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/ejd.2018.3476","article-title":"Rituximab revisited: successful management of severe childhood atopic dermatitis","volume":"29","author":"Duarte","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1760","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105790_bib1765","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard-2022-223016","article-title":"Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake","volume":"81","author":"Loza","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105790_bib1770","doi-asserted-by":"crossref","first-page":"e000382","DOI":"10.1136\/rmdopen-2016-000382","article-title":"DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105790_bib1775","first-page":"799","article-title":"Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28\u00a0using erythrocyte sedimentation rate in early rheumatoid arthritis","volume":"35","author":"Kuriya","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105790_bib1780","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5152\/eurjrheum.2020.19199","article-title":"Conversion among the 28-joint count activity indices for rheumatoid arthritis","volume":"7","author":"Singapore","year":"2020","journal-title":"Eur J Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:08:30Z","timestamp":1740100110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":178,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1297319X24001015"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105790","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105790"}}